Abstract OT1-01-04: A multicenter, phase 1b, first-in-human dose-escalation study of ADXS31-164, a Listeria monocytogenes -LLO immunotherapy, in patients with HER2-expressing solid tumors
Tan, AR, Olszanski, A, Golan, T, Mauro, D, Rugo, H
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Get full text
Journal Article
Abstract PD5-02: Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple-negative breast cancer beyond BRCA : (TOPACIO/Keynote-162)
Vinayak, S, Tolaney, SM, Schwartzberg, L, Mita, M, McCann, G, Tan, AR, Wahner Hendrickson, A, Forero, A, Anders, C, Wulf, G, Dillon, P, Lynce, F, Zarwan, C, Erban, J, Färkkilä, A, Zhou, Y, Buerstatte, N, Graham, JR, Arora, S, Dezube, B, Telli, ML
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Get full text
Journal Article
PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1)
Pohlmann, PR, Potter, DA, Chen, N, Mouabbi, JA, Rampurwala, M, Rayani, S, Tan, AR, Leon-Ferre, RA, Giridhar, K, Boughey, JC, Han, HS, Kennedy, LC, Walsh, EM, Tripathy, D, Jafari, S, Eklund, M, Nanda, R, Meric-Bernstam, F, Yee, D, Esserman, L
Published in JOURNAL OF CLINICAL ONCOLOGY (2024)
Get full text
Published in JOURNAL OF CLINICAL ONCOLOGY (2024)
Conference Proceeding
Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
TAN, Antoinette R, XIAOWEI YANG, BACHARACH, Stephen L, WHATLEY, Millie, CARRASQUILLO, Jorge A, BRAHIM, Jaime S, ETTENBERG, Seth A, LIPKOWITZ, Stan, SWAIN, Sandra M, HEWITT, Stephen M, BERMAN, Arlene, LEPPER, Erin R, SPARREBOOM, Alex, PARR, Allyson L, FIGG, William D, CHOW, Catherine, STEINBERG, Seth M
Published in Journal of clinical oncology (01.08.2004)
Published in Journal of clinical oncology (01.08.2004)
Get full text
Journal Article
Abstract OT2-6-13: A randomized phase 2 study of the triplet combination of ridaforolimus (RIDA), dalotuzumab (DALO) and exemestane (EX) compared to the ridaforolimus, exemestane doublet in high proliferation, estrogen receptor positive (ER+) advanced breast cancer
Rugo, HS, Tredan, O, Ro, J, Morales, SM, Musolina, A, Afonso, N, Ferreira, M, Park, KH, Cortes, J, Tan, AR, Blum, JL, Eaton, L, Mauro, D, Gause, C, Im, E, Baselga, J
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Get full text
Journal Article
Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer
Baselga, J, Morales, SM, Awada, A, Blum, JL, Tan, AR, Ewertz, M, Cortes, J, Moy, B, Ruddy, KJ, Haddad, T, Ciruelos, EM, Vuylsteke, P, Ebbinghaus, S, Im, E, Eaton, L, Prathiraja, K, Gause, C, Mauro, D, Rugo, HS
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Published in Cancer research (Chicago, Ill.) (15.12.2013)
Get full text
Journal Article
Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms
TAN, Antoinette R, HEADLEE, Donna, SENDEROWICZ, Adrian M, MESSMANN, Richard, SAUSVILLE, Edward A, ARBUCK, Susan G, MURGO, Anthony J, MELILLO, Giovanni, SUOPING ZHAI, FIGG, William D, SWAIN, Sandra M
Published in Journal of clinical oncology (01.10.2002)
Published in Journal of clinical oncology (01.10.2002)
Get full text
Journal Article
Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer
TAN, Antoinette R, XIAOWEI YANG, SWAIN, Sandra M, BERMAN, Arlene, SUOPING ZHAI, SPARREBOOM, Alex, PARR, Allyson L, CHOW, Catherine, BRAHIM, Jaime S, STEINBERG, Seth M, FIGG, William D
Published in Clinical cancer research (01.08.2004)
Published in Clinical cancer research (01.08.2004)
Get full text
Journal Article
Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer
Burstein, HJ, Sun, Y, Tan, AR, Dirix, L, Vermette, JJ, Powell, C, Zacharchuk, C, Badwe, RA
Published in Cancer research (Chicago, Ill.) (15.01.2009)
Published in Cancer research (Chicago, Ill.) (15.01.2009)
Get full text
Journal Article
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor
Lepper, Erin R., Swain, Sandra M., Tan, Antoinette R., Figg, William D., Sparreboom, Alex
Published in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (25.10.2003)
Published in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (25.10.2003)
Get full text
Journal Article
Nanostructured Proton-Conducting Membranes for Fuel Cell Applications
Tan, Ai Ren, Magno de Carvalho, Luisa, de Souza Gomes, Ailton
Published in Macromolecular symposia (01.11.2005)
Published in Macromolecular symposia (01.11.2005)
Get full text
Journal Article
Conference Proceeding
Reverse engineering from 3D mesh to ceramic product in the form of miranda kerr tea for one teapot in PT doulton Indonesia
Anggoro, P.W., Tan Wijaya, A.R., Yuniarto, T., Bayuseno, A.P., Jamari, J., Tauviqirrahman, M., Setyohadi, D.B.
Published in Cogent engineering (01.01.2021)
Published in Cogent engineering (01.01.2021)
Get full text
Journal Article